| Returns | 1W : 2.9% , 1M : -3.8%,1Y : 68.2% |
| LT : |
Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Average |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| AUROBINDO PHARMA LTD | 2.9% | -3.8% | 68.2% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 2% | 4.1% | 55.6% |
| DR REDDYS LABORATORIES LTD | -0.8% | -0.5% | 45.1% |
| DIVIS LABORATORIES LTD | 0.9% | 1.3% | 60.4% |
| CIPLA LTD | 2.9% | 0.8% | 87.3% |
| BIOCON LTD | 2% | 4.8% | 32.2% |
| LUPIN LTD | 4.7% | 6.7% | 54.3% |
| TORRENT PHARMACEUTICALS LTD | -0.3% | -2.5% | 12.2% |
| CADILA HEALTHCARE LTD | 1.6% | -3.2% | 66.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
18.35
P/E Calculated based on EPS of 48.32
[ Mar2020 - Consolidated Results ] 3.09
P/B Calculated based on Book Value of 286.92
[ Mar2020 - Consolidated Results ] 2.2
P/S Calculated based on Revenues of 23578.7 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
144% -8% 11% |
| Pledged Shares |
9.34 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
